GlucoTrack, Inc. (NASDAQ:GCTK) Sees Significant Decline in Short Interest

GlucoTrack, Inc. (NASDAQ:GCTK) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totaling 44,035 shares, a decrease of 98.0% from the April 30th total of 2,166,796 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 9,850,067 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of GlucoTrack in a research report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, GlucoTrack has a consensus rating of “Sell”.

Hedge Funds Weigh In On GlucoTrack

Several large investors have recently bought and sold shares of the business. Ikarian Capital LLC acquired a new position in GlucoTrack in the fourth quarter valued at approximately $177,000. Boothbay Fund Management LLC acquired a new position in GlucoTrack in the fourth quarter valued at approximately $52,000. Finally, Bank of America Corp DE lifted its holdings in GlucoTrack by 102,125.0% in the second quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock valued at $25,000 after buying an additional 4,085 shares during the period. 10.92% of the stock is currently owned by institutional investors and hedge funds.

GlucoTrack Trading Down 0.6%

NASDAQ:GCTK traded down $0.00 on Thursday, hitting $0.63. 136,087 shares of the stock were exchanged, compared to its average volume of 3,110,145. The company’s 50-day moving average price is $0.78 and its 200 day moving average price is $2.62. GlucoTrack has a 52 week low of $0.43 and a 52 week high of $15.90. The stock has a market capitalization of $3.96 million, a price-to-earnings ratio of -0.04 and a beta of 0.78. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.85 and a current ratio of 0.85.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.